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Introduction  
Pulsatile  drug  delivery  system  (PDDS)  is  based  on 
principle of rapid release of a certain amount of drug 
within  short  time  period  after  a  predetermined  off-
release period, lag time.
1Such novel drug delivery has 
been  attempted  for:  (i)  chronopharmacotherapy  of 
diseases  which  show  circadian  rhythms  in  their 
pathophysiology
2;  (ii)  avoiding  degradation  of  active 
ingredients  in  upper  GI  tract,  e.g.  proteins  and 
peptides
3; (iii) for time programmed administration of 
hormones and many drugs such as isosorbidedinitrate, 
respectively to avoid suppression of normal secretion 
of hormones in body that can be hampered by constant 
release of hormone from administered dosage form and 
development  of  resistance
4,5;  (iv)  to  avoid 
pharmacokinetic  drug–drug  interactions  between 
concomitantly  administered  drugs
6,  etc. 
Chronopharmacotherapy  for  rheumatoid  arthritis  has 
been  recommended  to  ensure  that  the  highest  blood 
levels  of  the  drug  coincide  with  peak  pain  and 
stiffness.
7 Morning stiffness associated with pain at the 
time  of  awakening  is  a  diagnostic  criterion  of  the 
rheumatoid  arthritis  and  these  clinical  circadian 
symptoms  are  supposed  to  be  outcome  of  altered 
functioning  of  hypothalamic–pitutary–adrenocortical 
axis.
8,9  A  pulsatile  drug  delivery  system  that  can  be 
administered  at  night  (before  sleep)  but  that  release 
drug  in  early  morning  would  be  a  promising 
chronopharmaceutic system. 
Oral pulsatile drug delivery systems that release drug 
after a lag period of 6–7 h usually release drug in large 
intestine 
10 however, the viscous contents of lower part 
of GI tract cause hindrance to the drug diffusion and 
also enzymatic degradation of some drugs makes it an 
unfavorable  site  for  drug  release.
11  Moreover,  the 
majority of drugs are preferentially absorbed from the 
upper part of the small intestine 
12 hence, drug release 
at  site  of  better  absorption  can  improve  therapeutic 
efficacy  of  drug.  This  is  of  more  concern  for  drug 
delivery that is meant for pulse drug release after a lag 
period of 5–6 h following oral administration of dosage 
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form.  A  blend  of  floating  and  pulsatile  principles  of 
drug delivery system would have the advantage that a 
drug  can  be  released  in  the  upper  GI  tract  after  a 
definite time period of no drug release (lag period). The 
major objectives of the present study were to develop a 
simple,  multiparticulate,  floating-pulsatile  drug 
delivery  system  for  obtaining  no  drug  release  during 
floating time followed by pulse drug release in small 
intestine.  Additionally,  multiple  unit  dosage  forms 
provide  many  relative  advantages  over  single  unit 
dosage  forms  such  as  predictable  GI  transit  time, 
greater product safety, etc..
13 
The  essential  features  of  this  conceptual  delivery 
system  exhibit  as  a  (a)  multiparticulate  system,  (b) 
combination of gastroretentive and pulsatile principles 
in  same  dosage  form,  (c)  single-step  formulation 
process  (d)  idealistic  drug  release  profile  that  is 
effective  at  morning  time  intended  for  a  particular 
pathological condition based on chronotherapy, and (e) 
having  low  drug  release  in  stomach  suited  for  non-
steroidal  anti-inflammatory  drug  (NSAID)  class  of 
drug. Piroxicam, for symptomatic relief in rheumatoid 
arthritis,  exhibits  better  toleration  than  indomethacin, 
naproxen,  and  enteric-  coated  acetylsalicylic  acid 
hence;  piroxicam  was  used  as  a  model  drug  in  this 
study.
14 
 
Materials and methods   
Materials 
Piroxicam,  PX  (Shasun  Chemicals  &  Drugs,  India), 
Eudragit  S100,  Eu  S100  (MW  ~  135  KDa,  Rohm 
GmbH, Germany), polyvinyl alcohol, PVA, (MW ~ 70 
KDa, 88% hydrolyzed, Sigma, Germany), and ethanol 
and  dichloromethane  (Merck,  Germany)  were  used. 
The Solvents were of analytical grade.  
 
Preparation of the microballoons 
PX (0.1- 0.6g) was dissolved with Eu S100 (0.6 g) in a 
mixed  solution  of  ethanol  (good  solvent,  5  ml),  and 
dichloromethane  (bridging  liquid,  5  ml).  The 
microballoons  were  prepared  by  slowly  adding  the 
resultant solution (during 10 min)  to 200 ml 0.1 N HCl 
containing  0.75  %  of  PVA  (at  25  °C)  placed  in  a 
cylindrical vessel (500 ml) equipped with three baffles 
under agitation (400 rpm) using a propeller type stirrer 
with four blades. After agitating the system for 20 min 
the  solidified  microballoons  were  recovered  by 
filtration. The resultant products were dried in an oven 
at 50 °C for 6 h.  
 
Determination of production yield and encapsulation 
efficiency of microballoons 
All  microballoon  formulations  were  prepared  in 
triplicate.  Microballoons  dried  at  50 °C  were  then 
weighed and the yield of microballoon preparation was 
calculated using the formula (Eq. (1)): 
Production yield (%) =
Practical  mass  (microballoons )
Theoretical  mass  (polymer  + drug ) ×100  
Eq. (1) 
Microballoons were crushed and powdered by using a 
mortar.  Accurately  weighed  of  this  powder  was 
extracted in ethanol. The solution was then filtered, a 
sample of 2ml was withdrawn from this solution and 
assayed  spectrophotometrically  to  determine  the  PX 
content of the microballoons. A calibration curve based 
on  standard  solutions  of  PX  in  ethanol  was  used  to 
calculate the PX concentration.  
The  encapsulation  efficiency  (%)  was  calculated 
by using following Equation (Eq. (2)). 
100 )
M
M
( (%) efficiency ion Encapsulat
l theoretica
actual   Eq. (2) 
Where  Mactual  is  the  actual  PX  content  in  weighed 
quantity of powder of microballoons and Mtheoretical is 
the  theoretical  amount  of  PX  in  microballoons 
calculated  from  the  quantity  added  in  the  fabrication 
process. The means of three assays were reported. 
Measurement of micromeritic properties 
Size distribution and mean diameter were determined 
by the sieving method. A total of 25 g of material was 
sieved  using  an  Erweka  vibration  sieve  (Erweka, 
Germany) through a nest of sieves. The vibration rate 
was set at 200 strokes/min and the sieving time was 10 
min. The powder fractions  retained by the  individual 
sieves  were  determined  and  expressed  as  mass 
percentages.  The  morphology  of  the  microballoonss 
was observed by optical microscopy (Nikon Labophot, 
Tokyo, Japan). Apparent particle density and roundness 
was  determined  by  the  projective  image  method  as 
follows.  Microballoons  were  placed  on  a  glass  plate 
and  Heywood  diameter,  microballoon  number, 
circumference  of  a  projective  image  and  area  of  a 
projective image were measured by an Image analyzing 
software  (scion  image  analyzer).  Subsequently,  the 
apparent particle density and roundness were calculated 
according to Eq. (3) and Eq. (4), respectively. 
 
Apparent particle density  ?/? = ?/ (𝜋𝑑3 𝑛/6)   Eq. (3) 
 
where W = weight of microballoons, V = volume of 
microballoons, d = Heywood diameter, and n = number 
of microballoons. 
Roundness of microballoons = 𝐿2/4𝜋𝑠        Eq. (4) 
where L = circumference of a projective image and S = 
area  of  a  projective  image.  When  the  roundness  of 
microballoons was close to 1, the microballoons closely 
resembled spherical particles. 
Flowability of the crystals was assessed by determining 
the angle of repose and the compressibility index (Carr 
index). The angle of repose was measured by a fixed 
funnel method.
15 The Carr index 
16,17 is a measure of 
the  propensity  of  a  powder  to  consolidate.  Changes 
occurring  in  packing  arrangement  during  the  taping 
procedure are expressed as the Carr index (CI).  
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CI= [(tapped density – bulk density) / tapped density]  100    
Eq. (5) 
The Carr index reflects the packability of the powders, 
and there is also a correlation between the Carr index 
and  the  flowability  of  the  crystals.  The  results 
presented are mean value of six determinations. 
Differential scanning calorimetery (DSC)  
The  thermal  characteristics  of  the  microballoons  and 
pure  drug  were  determined  using  a  differential 
scanning calorimeter (DSC60, Shimadzu, Japan). After 
calibration with indium and lead standards, samples of 
the crystals (3–5 mg) were heated (range 25-300°C) at 
10 °C/min in hermetically sealed aluminum pans.  
X-ray powder diffraction (XRPD)   
In order to investigate polymorphism X-ray was used. 
The  cavity  of  the  metal  sample  holder  of  the  X-ray 
diffractometer  was  filled  with  the  ground  sample 
powder  and  then  smoothed  with  a  spatula.  X-ray 
diffraction pattern of PX samples was obtained using 
the  X-ray  diffractometer  (Siemens,  Model  D5000, 
Germany)  at  40  kV,  30  mA  and  a  scanning  rate  of 
0.06°/min  over  the  range  2θ=5–40,  using  CuKα1 
radiation of wavelength 1.5405A°. 
 
Buoyancy percentage 
Microballoons (100 mg) were spread over the surface 
of a USP XXIV dissolution apparatus (type II) filled 
with 900 mL 0.1 mol L
–1HCl containing 0.02% Tween 
20.
18 The medium was agitated with a paddle rotating 
at 100 rpm for 8 h. The floating and the settled portions 
of  microballoons  were  recovered  separately.  The 
microballoons  were  dried  and  weighed.  Buoyancy 
percentage was calculated as the ratio of the mass of 
the microballoons that remained floating and the total 
mass of the microballoons. 
 
In vitro release studies 
The  in  vitro  dissolution  of  microballoons  was 
determined with a USP rotating paddle method (900 ml 
0.1 N HCl or pH 7.4 phosphate buffer; 100 rpm; 37
oC; 
n =3). At preset time intervals aliquots were withdrawn 
and  replaced  by  an  equal  volume  of  dissolution 
medium  to  maintain  constant  volume.  After  suitable 
dilution,  the  samples  were  analyzed 
spectrophotometrically at 333.2 and 349.2 nm for the 
0.1 N HCl and pH 7.4 phosphate buffer, respectively. 
 
Results and discussion  
The microballoons prepared in this study, as observed 
in Figure 1, were near spherical in shape with a central 
hollow  core  surrounded  by  a  shell  as  shown  in  the 
photograph  of  a  broken  half  of  a  microballoon.  The 
cavity was supposedly formed as follows according to 
the  previous  reports.
19-21  As  soon  as  the  polymer 
solution was added to the aqueous medium, the ethanol 
diffused  rapidly  from  the  droplets  of  the  polymer 
solution because of higher solubility of ethanol in water 
than dichloromethane.  As ethanol diffuses through the 
aqueous  solution,  accompanied  by  simultaneous 
diffusion of water inside the sphere, the solubility of 
the polymer in the droplet is drastically reduced and 
reduces the coprecipitation of drug and polymer at the 
interface of the emulsion droplet, forming a solid shell 
covering  the  droplet.  Dichloromethane  evaporation 
appeared to be especially related to cavity formation in 
microballoons  and  properties  of  formed  solid  shell.  
Dichloromethane remaining as the central core diffused 
slowly due to its low water solubility. Therefore, the 
diffusion of dichloromethane began late, after the initial 
solidification,  and  formed  a  central  hollow  structure. 
As  shown  in  photomicrographs  the  shape  and  shell 
thickness  of  the  microballoons  were  different  among 
the formulations.  Preparation at higher polymer/drug 
ratio  provided  microballoons  with  a  thin  shell  as  to 
crumble upon touching and roundness close to 1 while 
the microballoons prepared at lower polymer/drug ratio 
showed  thicker  shell,  probably  arising  as  a  trace  of 
solvent evaporation. 
 
 
Figure  1.  Particle morphology  of  microballoons  (I):  polymer: 
drug (1:1) and (II) polymer: drug (:1), right photographs (×100) 
left photographs (×500). 
These  results  could  be  explained  by  considering  the 
mechanism of formation of microballons as previously 
noted. Microballoons shells were conveniently formed 
by  coprecipitation  of  drug  and  polymers,  as  well  as 
successive evaporation of the inner solvent.   
It is assumable that any factor which could modify the 
time  needed  to  reach  the  physical  state-transition 
boundaries  of  the  polymeric  solution  (solution-gel-
glass) during the hardening process will be effective in 
the polymer precipitation and consequently in solvent 
evaporation rate.
22The polymer -to- drug ratio can be a 
critical  factor  during  microballoon  formation.  The 
increase in polymer/drug ratio leads to a shorter time 
for the composition of the polymer solution to reach the 
viscous (gelation) boundary, resulting in a rapid film-
like membrane formation on the droplets periphery. If 
the film-like polymeric membrane is quickly solidified,  
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the  microballoon  structure  is  more  fixed  and  thus 
solvent  evaporation  is  delayed.
22As  previously 
explained  a  slow  rate  of  evaporation  of 
dichloromethane  led  to  formation  of  porous 
microballoons  as  dichloromethane  remained  in  the 
pockets preventing formation of a hard polymer shell. 
Thus it can be concluded that thin and porous structure 
of the microballoons shell prepared at higher polymer 
/drug ratio was attributed to slower rate of evaporation 
of dichloromethan as a consequence of rapid polymer 
shell formation.  
On  the  other  hand,  the  slower  solidification  of  the 
polymeric  shell  at  the  droplet  periphery  due  to 
decreasing polymer/drug ratio, delays creation of shell 
barrier to mass transfer, increases solvent evaporation 
rate  and  consequently  increases  the  rigidity  of  the 
polymer shell.  
Microballoons  displaying  diameters  of  between  250 
and 380 µm (Table 1). Theparticle size increased with 
increasing the polymer / drug ratio. This is due to the 
increase in viscosity of the solution and the decrease in 
stirring efficiency. Also with increasing polymer/drug 
ratio,  the  hardening  time  of  the  microballoons  was 
shortened. Consequently, a shorter time was provided 
for  the  breakup  of  droplets  and  larger  microballoons 
were formed. Flowability results are shown in Table 1 
as  expressed  in  term  of  angle  of  repose  and  the 
compressibility  index.  All  formulations  showed  high 
flowability as angle of repose ranged between 17.5 to 
23 
o and the compressibility index ranged between7% 
to 11%. The excellent flow property indicates that the 
floating  microballoons  produced  are  non-aggregated 
(Table 1). 
 
Table 1. Mean diameter, angle of repose, Carr’s Index, yield and encapsulation efficiency of samples 
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Untreated PX  10.75±0.36  -  35.8±1.3  32.3±0.6  -  -  -  - 
Eu:PX 
1:1  250±110  0.98±0.02  17.5±0.9  7.0± 0.2  73.8±0.8  90.8±0.5  62.5±1.0  0.5±0.03 
2:1  290±80  0.96±0.03  20.7±1.0  10.8±0.3  70.6±1.0  92.5±0.6  77.7±0.9  0.29±0.03 
4:1  310±260  0.93±0.03  19.1±1.5  9.1±0.1  68.8±0.9  95.4±0.4  80.2±0.8  0.22±0.04 
6:1  380±220  0.92±0.02  23.0±0.6  11.0±0.3  65.5±1.1  98.3±0.4  85.4±1.1  0.19±0.04 
 
Yield and encapsulation efficiency  
The  percentage  yield  of  floating  microballoons 
determined by weighing after drying was73, 70, 68 and 
65% for microballoons prepare at 1:1, 2:1, 4:1 and 6:1 
polymer/drug ratios, respectively. Decreasing yield of 
microballoons  by  increasing  polymer/drug  ratio  (p< 
0.05) may be due to higher viscosity of polymer which 
resulted in agglomeration of droplets and adhering to 
the vessel wall and propeller. As can be seen in Table 
1,  the  encapsulation  efficiencies  were  high  in  all 
formulations  (>90%).The  high  encapsulation 
efficiencies  probably  result  from  the  poor  water 
solubility  of  the  drug  in  the  external  aqueous  phase. 
Slight  loss  of  drug  may  be  due  to  some  dissolution 
prior to drop formation or during the hardening process 
in  polyvinyl  alcohol  solution  mixed  with  diffused 
ethanol.
23The  ratio  ‘polymer  /  drug’  affected  the 
resulting  encapsulation  efficiency.  With  more 
polymer/drug  ratios,  higher  encapsulation  efficiencies 
were  produced.  For  instance,  PX  encapsulation 
efficiency  was  increased  from  90.8%  to  98.3  %  as 
polymer:drug ratio was increased from 1:1 to 6:1. 
This can either be attributed to the increased probability 
for the drug to be entrapped within the microballoons 
with increasing ratio of polymer to drug, and/or to the 
decreasing drug loss into the external water phase under 
these conditions.  These  results  can  be  also  related  to 
hardening  process  of  microballoons.    Increasing 
polymer/drug ratio leads to a more viscous droplets and 
consequently faster solidification rate of microballoons. 
Therefore, the microballoon structure is more fixed and 
thus  solvent  and  nonsolvent  counter-  diffusion  is 
delayed.  As  a  result,  less  water  may  be  allowed  to 
diffuse into the droplets and consequently less amount 
of drug will be carried by the solvent into the aqueous 
phase.
22 
 
DSC and X-ray diffraction results  
The  DSC  curves  and  X-ray  diffraction  pattern  of  the 
microballoons  are  shown  in  Figure  2  and  Figure  3, 
respectively. As shown in Figure 2, the melting peak of 
the  drug  in  the  microballoons  disappeared  with 
increasing the  ratio  of  polymer/drug from  1:1  to  2:1, 
although the melting peak was observed in the physical 
mixtures of the drug and polymer with the same ratio. 
These  indicated  that  PX  had  been  disordered  in  the 
microballoons  at  2:1  polymer/  drug  ratio,  suggesting 
that PX had been highly dispersed at this ratio, so as 
amorphous state.  
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Figure  2.  DSC  scans  of  1)  polymer  2)  untreated  drug    
3) polymer:drug (1:1), 4) physical . 
Figure  3.  The  X-ray  diffraction  patterns  of  untreated 
drug  and  microballoons  prepared  at  polymer:  drug  ratios 
of 1:1 and 2:1. 
This  was  further  supported  by  the  X-ray  analysis 
data  given  in  Figure  3,  which  shows  the 
representative  diffraction  patterns  for  the  pure 
drug,  the  microballoons  prepared  at  1:1  and  2:1 
polymer/drug  ratios.  Characteristic  peaks  of 
piroxicam  appeared  at  a  diffraction  angle  of  2θ,  at 
8.99,  15.76,  23.02  and  25.85°.  These  values  were 
comparable  to  those  reported  for  form  I  of  PX.
24 
Crystalline  peaks  were  observed  in  the 
1:1polymer/drug  ratio  but  no  crystalline  peaks  of 
PX  were  found  in  the  microballoons  at  2:1 
polymer  /drug  ratio.  The  scans  and  XRPD 
patterns  of  microballoons  produced  at  4:1  and  6:1 
polymer/drug  ratios  are  similar  to  2:1  ratio  and 
hence  not  all  of  them  are  shown.  In  summary,  the 
DSC  and  XRPD  data  indicated  no  sign  of 
interaction  between  the  drug  and  the  polymer  and 
also  showed  that  the  PX  inside  the  microballoons 
was changed only in its crystallinity. 
Floating properties 
To assess the floating properties, microballoons were 
placed  in  0.1  HCl  containing  0.02%  polysorbate,  in 
order to simulate surface tension of human gastric juice 
(35-50mN/m2).
18 Buoyancy of beads is directly related 
to  performance  of  floating-pulsatile  drug  delivery 
system since lag time for beads is equivalent to their 
floating time. 
Apparent  particle  density  and  buoyancy  of 
microballoons prepared at various polymer/drug ratios 
were measured. It is noticeable that during the floating 
test, no swelling or gelation of the microballoons was 
found. In accordance with polymer/drug ratio (1:1, 2:1, 
4:1 and 6:1), buoyancy and apparent particle density of 
the  resulting  microballoons  varied  distinctly  as 
presented  in  Table  1.  According  to  results,  by 
increasing the polymer/drug ratio, the buoyancy of the 
microballoons  largely  increased,  accompanied  by 
decreased  particle  density.  For  instance,  the 
microballoons  prepared  at  6:1  polymer/drug  showed 
highest buoyancy as a consequence of lowest particle 
density. Therefore, it was concluded that the buoyancy 
of  the  microballoons  appeared  to  be  more  greatly 
affected  by  the  apparent  particle  density.  Decreasing 
apparent particle density with increasing polymer /drug 
ratio could be explained by considering the mechanism 
of formation of microballons as previously noted. As 
can  be  seen  in  Figure  1,  preparation  at  higher 
polymer/drug ratio provided larger microballoons with 
thinner  shell.  As  previously  described,  this  was 
attributed  to  slow  rate  of  evaporation  of 
dichloromethane  as  a  consequence  of  rapid  polymer 
shell formation.  
Moreover, in other researches, it was observed that the 
microballoons of larger size, showed the longer floating 
time. Therefore, increasing buoyancy of  microballons 
by  increasing  the  polymer/drug  ratio  may  also  be 
attributed  to  larger  particle  size  by  increasing 
polymer/drug ratio (Table 1).
25,26 
 
In vitro drug release  
Release of the drug from Eu S100 based microballoons 
was  evaluated  in  pH  1.2  and  7.4.  Release  studies  in 
SGF  for  6  h  showed  only  0.7–11%  cumulative  drug 
release from beads of different batches (Figure 4). 
 
Figure 4. Release of drug from microballoons into 0.1 N HCl (± 
SD., n=3).    
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Since the acrylic polymer used is not soluble in acidic 
pH  and  starts  to  dissolve  above  pH  7
27,  no  marked 
amount of drug was released from the microballoons in 
SGF. Drug release from Eu S100 in SGF took place 
only through diffusion and drug release in SIF (pH 7.4) 
might  have  involved  both  mechanisms  i.e.  diffusion 
and erosion.  
All the batches of beads showed fast disintegration and 
drug release in SIF due to pH dependent dissolving of 
Eudragit S. Complete drug dissolution from beads of 
each batch occurred during 3h in SIF, which would be 
useful  in  in  vivo  drug  absorption  from  large  surface 
area of small intestine. Small intestinal transit time for 
a drug formulation or for a meal is known to be almost 
constant at about 3 h.
28 As shown in Figure 5, although 
the  drug  release  from  beads  of  all  batches  was 
sufficiently  rapid  in  SIF,  the  composition  of  bead 
showed significant effect on drug release rate and the 
drug  release  was  inversely  related  to  polymer/drug 
ratio. For example, batches prepared by using 6:1or 4:1 
polymer/drug  ratios  showed  marked  slower  drug 
release  than  beads  prepared  by  using  2:1or  1:1 
polymer/drug  ratios.  This  significant  effect  of 
polymer/drug  ratio  on  drug  release  in  SIF  may  be 
attributed  to  formation  of  stronger  and  thicker  gel 
formation  with  increase  in  polymer/drug  that  restrict 
the drug diffusion through the beads. 
 
Figure  5.  Release  of  drug  from  microballoons  into  pH 
7.4 phosphate buffer (± SD., n=3). 
Conclusion  
As  results  showed,  properties  (buoyancy,  apparent 
particle density, size and sphericity) of microballoons 
varied  according  to  the  polymer/drug  ratio. 
Microballoons  prepared  at  polymer/drug  ratio  higher 
than 2:1 were so brittle as to crumble upon touching 
and  the  buoyancy  was  higher  probably  due  to  lower 
apparent particle densities of these microballoons. The 
floating  test  revealed  that  approximately  85%  of  the 
microballoons  with  6:1  polymer/drug  ratio  were  still 
floating after 8h. During the floating test, no swelling 
or  gelation  of  the  microballoons  was  found,  which 
suggested that they were dispersed individually in the 
stomach without adhesion to the mucosa. This property 
should  avoid  local  irritation  due  to  a  localized 
overdose, which frequently occurs with the bioadhesion 
system. The beads showed fast drug release in SIF after 
sufficient  floating  time  in  SGF  where  no  noticeable 
drug released. In conclusion, the piroxicam-loaded Eu 
S100 microballoons, prepared using a solvent diffusion 
method, have the qualities suitable for their successful 
use as pulsatile drug delivery system. 
 
Acknowledgment 
The financial support from the Drug applied Research 
Center  of  Tabriz  University  of  Medical  Sciences  is 
greatly acknowledged. 
 
Conflict of interest 
The authors report no conflicts of interest. The authors 
alone are responsible for the content and writing of the 
paper. 
 
References 
1.  Kikuchi A, Okano T. Pulsatile drug release control 
using hydrogels. Adv Drug Deliv Rev 2002; 54:53–
77. 
2.  Sawada  T,  Kondo  H,  Nakashima  H,  Sako  K, 
Hayashi M. Time-release compression-coated core 
tablet  containing  nifedipine  for 
chronopharmacotherapy.  Int  J  Pharm  2004; 
280:103–111. 
3.  Rubinstein  A,  Tirosh  B,  Baluom  M,  Nassar  T, 
David A, Radai R, Gliko-Kabir I, Friedman  M. The 
rationale for peptide drug delivery to the colon and 
the potential of polymeric carriers as effective tools. 
J Control  Release 1997; 46:59–73. 
4.  Terasawa E, Keen KL, Mogi K, Claude P. Pulsatile 
release  of  luteinizing  hormone-release  (LHRH)  in 
cultured LHRH neurons derived from the embryolic 
olfactory  placode  of  the  rhesus  monkey. 
Endocrinology 1999; 140:1432–1441. 
5.  Charloux  A,  Gronfier  C,  Lonsdorfer-Wolf  E, 
Piquard  F,  Brandenberger  G.  Aldosterone  release 
during  the  sleep-wake  cycle  in  humans.  Am  J 
Physiol 1999; 276: E43–E49. 
6.  Sawada  T,  Sako  K,  Yoshihara  K,  Nakamura  K, 
Yokohama  S,  Hayashi  M.  Timed-release 
formulation to avoid drug–drug interaction between 
diltiazem  and  midazolam.  J  Pharm  Sci  2003;  92: 
790–797. 
7.  Stehlin I. A time to heal: chronotherapy tunes in to 
body’s rhythms. FDA Consumer 1997; 31:16. 
8.  Crofford  LJ,  Kalogeras  KT,  Mastorakos  G, 
Magiakou MA, Kanik KS, Gold PW, Chrousos GP, 
Wilder  RL.  Circadian  relationships  between 
interleukin  (IL)-6  and  hypothalamic-pitutary-
adrenal  axis  hormones:  failure  of  IL-6  to  cause 
sustained  hypercortisolism  in  patients  with  early 
untreated rheumatoid arthritis. J Clin Endocr Metab  
1997; 82: 1279–1283. 
9.  Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli 
A. Circadian rhythms in RA. Ann Rheum Dis 2003; 
62: 593–596.  
|   61 
Piroxicam floating-pulsatile drug delivery system 
 
Advanced Pharmaceutical Bulletin, 2011, 1(2), 55-61 
0 
Copyright © 2011 by Tabriz University of Medical Sciences 
10. Niwa  K,  Takaya  T,  Morimoto  T,  Takada  K. 
Preparation  and  evaluation  of  a  time-controlled 
release  capsule  made  of  ethylcellulose  for  colon 
delivery of drugs. J Drug Target 1995; 3: 83–89. 
11. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner 
E,  Friedman  M.  Pharmacokinetic  and 
pharmacodynamic aspects of gastroretentive dosage 
forms. Int J Pharm  2004; 277: 141–153. 
12. Rouge N, Buri P, Doelker E. Drug absorption sites 
in  the  gastrointestinal  tract  and  dosage  forms  for 
site-specific delivery. Int J Pharm 1996; 136: 117–
139. 
13. Ritschel WA. Targeting in the gastrointestinal tract: 
new approaches. Methods Find Exp Clin Pharmacol 
1991; 13: 313–336. 
14. Heynen G. Toleration and safety of piroxicam. Eur 
J Rheumatol Inflamm 1987; 8:86–93. 
15. Pilpel N. The flow properties of magnesia. J Pharm 
Pharmacol 1964; 16: 705–16. 
16. Carr RL. Evaluation flow properties of solids. Chem 
Eng 1965; 72:163–8. 
17.  Carr RL. Classify flow properties of solids. Chem 
Eng 1965; 72:69–72. 
18. El-Gibaly I. Development and in vitro evaluation of 
novel floating chitosan microcapsules for oral use: 
comparison  with  non  floating  chitosan 
microballoons. Int J Pharm 2002; 249: 7–21. 
19. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. 
Physicochemical  properties  to  determine  the 
buoyancy of hollow microballoons (microballoons) 
prepared by the emulsion solvent diffusion method. 
Eur J Pharm Biopharm 2003; 55:297–304.  
20. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh 
Y.  Preparation  of  multiple  unit  hollow 
microballoons  (microballoons)  with  acrylic  resin 
containing  tranilast  and  their  drug  release 
characteristics  (in  vitro)  and  floating  behavior  (in 
vivo). J Control  Release 1991; 16:279–290.  
21. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh 
Y.  Hollow  microballoons  for  use  as  a  floating 
controlled  drug  delivery  system  in  the  stomach.  J 
Pharm Sci 1992; 81:135–140.  
22. Re MI, Biscans B. Preparation of microballoons of 
Ketoprofen  with  acrylic  polymers  by  a  quasi-
emulsion  solvent  diffusion  method.  Powder 
technology 1999; 101: 120-133. 
23. Zaniboni HC, Fell JT, Collett JH. Production and 
characterization of enteric beads. Int J Pharm 1995; 
125:151-155. 
24. Vrecer F, Vrbinc M, Meden A.Characterization of 
piroxicamcrystal  modifications. Int J Pharm 2003; 
256: 3-15. 
25. Jain  SK,  Awasthi  AM,  Jain  NK,  Agrawal  GP. 
Calcium silicate based microballoons of repaglinide 
for  gastroretentive  floating  drug  delivery: 
Preparation and in vitro characterization. J Control  
Release 2005; 107: 300-309. 
26. Singh AN, Pathak K. Development and evaluation 
of dual controlled release microballoons containing 
riboflavin  and  citric  acid:  in  vitroandin 
vivoevaluation. J Microencapsul 2011; 28: 442-54. 
27. Yoo  JW,  Giri  N,  Lee  CH.  pH-sensitive  Eudragit 
nanoparticles  for  mucosal  drug  delivery.  Int  J 
Pharm 2011; 403: 262-267. 
28.  Davis  SS,  Hardy  JG,  Fara  JW.  Transit  of 
pharmaceutical  dosage  forms  through  the  small 
intestine. Gut 1986; 27: 886–892. 
 